NNOX Alert: Contact Kirby McInerney on Securities Violations!

Prepared for: Unknown Publisher

Company Overview

Nano-X Imaging Ltd. (NASDAQ: NNOX) is an Israel-based medical imaging technology company focused on developing a novel digital X-ray source and end-to-end imaging solution (www.nanox.vision). The company’s flagship product is the Nanox.ARC – a multi-source 3D digital X-ray imaging system designed to be significantly more cost-effective and accessible than traditional medical imaging hardware (www.nanox.vision). Through its ecosystem (including Nanox.AI software, cloud services, and teleradiology via USARAD), Nanox aims to provide a seamless “scan-to-diagnosis” platform that expands the reach of imaging beyond hospitals and supports early disease detection (www.nanox.vision) (www.nanox.vision). Founded in 2018, Nanox remains a development-stage company with limited operating history and has yet to achieve profitability (www.sec.gov). Its vision of affordable, preventive health imaging has attracted investor attention, but also skepticism from some industry observers and short-sellers (who have controversially likened Nanox to “Theranos 2.0” in the past) (www.fool.com).

Dividend Policy & Shareholder Returns

NNOX has no dividend history and does not currently return cash to shareholders. The company has never declared or paid a dividend, and management has “no immediate plans” to initiate dividends given the firm’s need to reinvest in growth (www.sec.gov). In fact, Nanox explicitly states that for the foreseeable future it intends to retain any earnings to fund operations and expansion, rather than distribute cash to investors (www.sec.gov). This policy is unsurprising for a development-stage company that is incurring losses and requires capital for R&D and commercialization. Investors should not expect any near-term income from NNOX in the form of dividends (www.sec.gov). (Traditional REIT metrics such as FFO/AFFO are not applicable here, since Nanox is not profitable and operates in the medical technology sector, not real estate.) Moreover, Nanox has not engaged in share buybacks; instead it has raised equity capital to finance its activities, diluting shareholders over time (discussed further below).

Leverage and Debt Maturities

Nanox maintains a light debt load, relying mostly on equity financing to date. As of December 31, 2022, the company’s total liabilities were approximately $71 million against $363 million in total assets (www.sec.gov), reflecting low leverage. The only significant debt reported at that time was a long-term loan of about $3.8 million (provided to its Nanox Korea subsidiary) (www.sec.gov). This loan bears interest at a market rate and constitutes the majority of Nanox’s interest-bearing debt. In practical terms, $3.8M is a very small debt for a company that had over $100M in cash and investments as of end-2022 (www.sec.gov). There are no known large bond obligations or complex debt instruments in Nanox’s capital structure – no outstanding convertible notes or significant bank facilities have been disclosed in filings. The debt maturity profile is therefore minimal; Nanox does not face major near-term debt repayments that could strain its finances. Any lease obligations or earn-out liabilities from acquisitions (the company has a ~$5–6M contingent earn-out on its books) are modest in scale (www.sec.gov). Overall, Nanox’s balance sheet has been financed primarily through equity raises (IPO in 2020 and subsequent offerings) rather than debt, which gives it flexibility but also means dilution risk for shareholders.

Liquidity and Coverage

Liquidity is a key concern for Nanox, as the company is burning cash while it ramps up commercialization. As of mid-2024, Nanox had approximately $64.2 million in cash, cash equivalents, restricted deposits, and marketable securities (investors.nanox.vision). This represented a decline from $82.8M at 2023 year-end, due to negative operating cash flow of about $17.9M in the first half of 2024 (investors.nanox.vision). By Q4 2025, losses had accelerated – the company disclosed a net loss of $33.4M for that quarter alone (www.globenewswire.com) – implying that cash reserves would have dwindled further by early 2026. Nanox’s cash “runway” (how long its cash can cover operations) appears limited to roughly 1–2 years unless additional capital is raised. In fact, Nanox filed a $100 million mixed securities shelf offering in March 2026 to bolster its financial position (intellectia.ai). This shelf registration indicates that the company is prepared to issue new equity or other securities to raise up to $100M as needed – a move that would dilute existing shareholders but provide vital cash.

In terms of coverage ratios, traditional metrics like interest coverage are not very meaningful for Nanox currently. The company’s interest expense is minimal – for example, only ~$71 thousand of interest was paid in the first half of 2024 (investors.nanox.vision) – so its interest coverage (EBITDA/interest) is more a formality than a constraint. The far more significant “coverage” issue is whether Nanox’s operating cash burn is covered by its available liquidity. With roughly $18M in operating cash outflow over six months (H1’24) (investors.nanox.vision) and potentially higher burn in 2025, the company’s cash coverage of its own expenses was on the order of several quarters. This reinforces why management moved to secure additional financing. Nanox does not have a debt service coverage problem (given low debt), but it does have a funding coverage challenge – it must continuously cover R&D, manufacturing, and SG&A costs with a shrinking pool of cash. Until it can substantially increase revenues or reduce its cost burn, Nanox’s viability depends on external funding infusions (equity or partnerships) to cover its cash needs.

Valuation

Valuing NNOX is difficult because the company is not yet profitable and has relatively small revenues. At the current share price around $2–3, Nanox’s market capitalization is roughly $180 million (intellectia.ai). After accounting for its cash on hand, the enterprise value (EV) is approximately $129M (intellectia.ai). On an EV/Sales basis, the stock still trades at a high multiple of recent revenue – Nanox generated only $13 million in revenue for full-year 2025 (intellectia.ai), so the current EV is about 10 times 2025 sales (and market cap is ~14x sales). This highlights that investors are valuing Nanox not on its historical results, but on its future potential to scale up revenue. For 2026, management has guided for ~$35M in revenue (implying significant growth) (intellectia.ai). Even if that target is met, the stock’s EV would be ~3.7x 2026E sales at present pricing – still a rich multiple for a company that would likely remain unprofitable in 2026. Traditional valuation metrics like P/E or EV/EBITDA are not meaningful because Nanox’s earnings are negative (EBITDA is well below zero). Price-to-book is one metric we can consider: as of year-end 2022 Nanox’s book value per share was roughly $4 (total equity ~$292M over ~70M shares) – meaning the stock now trades below book value, reflecting diminished market confidence. However, a portion of that book value is intangibles and goodwill from acquisitions (e.g. Nanox’s AI and teleradiology units), which the market may discount given recent impairments.

For a sense of relative valuation: established medical imaging companies (like divisions of GE Health, Siemens Healthineers, etc.) trade at much lower multiples of sales but have large revenues and profits. Nanox, by contrast, is being valued more like a speculative high-growth medtech startup. The stock reached an all-time high of ~$89 in early 2021 during peak optimism (www.macrotrends.net), but has since collapsed to the low-single-digits, wiping out over 95% of its market value. Today’s pricing suggests skepticism – yet it still embeds the assumption that Nanox’s novel technology will gain traction commercially. Some valuation models even hint at upside if execution improves (one analysis estimated an ~$8 per share intrinsic value) but also flag Nanox as a “value trap” due to its precarious finances and risks (www.macrotrends.net). In summary, NNOX’s current valuation can be seen as option value: investors are paying a small fraction of the company’s previous peak value, essentially betting that Nanox’s X-ray system can eventually disrupt the market. If the company fails to execute, the downside could be a further slide (or even zero); if it succeeds, the upside could be significant – but that success is far from guaranteed, as discussed below.

Risks and Red Flags

NNOX carries substantial risks, and several red flags have been raised regarding the company’s business and governance. Key risk factors and concerns include:

– Limited Operating History & Ongoing Losses: Nanox is a young, development-stage company with a very limited track record. It has incurred losses every year and explicitly warns that it “may never… achieve significant revenues or reach profitability” (www.sec.gov). The business model (selling a novel imaging-as-a-service solution) remains unproven at scale. With only a handful of systems deployed and minimal revenue so far, there is a risk that Nanox will fail to commercially launch the Nanox.ARC successfully or achieve the required market acceptance (www.sec.gov). In short, Nanox might never generate the level of revenue needed to sustain the business.

– Product Adoption & Regulatory Hurdles: The Nanox.ARC system and related services face significant regulatory and market adoption challenges. The company needs approvals from regulators in each target market and must convince hospitals and radiology providers to use its new technology. Any delays or denials in regulatory clearance can be critical. For instance, in 2021 the FDA put Nanox’s multi-source Nanox.ARC submission on hold pending more information, which the company had to address within 180 days (www.businesswire.com). Events like this highlight the regulatory risk – approval processes can be uncertain and lengthy. Moreover, even with FDA clearance, physician adoption is not guaranteed; radiologists may be skeptical of a new, cheaper imaging device until there is extensive clinical evidence of its efficacy. Nanox itself acknowledges that without “widespread market acceptance” of the Nanox System, it will not generate the necessary revenue to support its business (www.sec.gov). This is a classic chicken-and-egg problem: the technology must prove itself in real-world use, but proving itself requires market adoption.

– History of Short-Seller Allegations: Nanox has been the target of notable short-seller reports and fraud allegations. In September 2020, shortly after the company’s IPO, Citron Research and other analysts accused Nanox of being essentially a hoax, even dubbing it “Theranos 2.0” (www.fool.com). These critics claimed Nanox had not demonstrated a working product at scale and compared its promotional claims to the infamous blood-testing startup scandal. While Nanox vehemently denied the fraud accusations, the controversy led to heightened volatility in the stock. Such allegations are a red flag as they underscore concerns about the credibility of Nanox’s technology and disclosures. The stock price plummeted in the wake of these reports (www.nasdaq.com), and the company’s reputation suffered damage among investors. Nanox has since made progress – including obtaining FDA clearances for certain features and prototypes – but the shadow of those early fraud claims has not fully disappeared.

– Legal and Compliance Risks: Related to the above, Nanox has faced investor litigation. A class-action lawsuit was filed in 2021 alleging that the company made false or misleading statements regarding its FDA submission timeline and device capabilities (www.businesswire.com). Specifically, after Nanox announced an FDA submission in June 2021, it later revealed the FDA had put that application on hold pending more data, causing the stock to drop ~9.5% in one day (www.businesswire.com). Plaintiffs claimed Nanox failed to disclose material information, violating securities laws. As of late 2021, investors were encouraged to join this lawsuit (www.businesswire.com). Fast-forward to 2026, and in the wake of recent developments, new legal scrutiny has emerged: Kirby McInerney LLP (a law firm specializing in shareholder rights) announced in April 2026 that it is investigating Nano-X and its management for potential securities law violations (www.globenewswire.com). This was prompted by the steep share price drop on April 20, 2026, after Nanox’s Q4 results and CFO departure news. While this is only an investigation (no lawsuit filed yet) (www.globenewswire.com), it raises another red flag – suggesting that Nanox’s disclosures or business practices surrounding these events might be called into question. Ongoing legal challenges could divert management attention, incur costs, and damage the company’s reputation.

– Financial Position & Dilution Risk: Nanox’s financial sustainability is uncertain. The company continues to burn cash each quarter and will need additional capital soon. Its decision to register a $100M shelf offering is a warning sign that current cash may not last through 2026 (intellectia.ai). If Nanox issues a large amount of new shares or convertible securities to raise funds, existing shareholders will face dilution. The stock already dropped sharply when the shelf registration and Q4 loss were made public (a 25% one-day decline) (www.globenewswire.com), reflecting investor concern about dilution and financial stress. There is a risk that Nanox might even struggle to raise enough capital if market sentiment remains poor – its share price is low, and issuing $100M of equity at ~$2 per share would mean a very large increase in shares outstanding. Furthermore, the recent $17.5M asset impairment suggests the company invested in manufacturing capabilities that are not panning out, potentially necessitating write-offs and additional spending elsewhere (www.globenewswire.com). In sum, Nanox faces a going-concern risk in the medium term: without successful fundraising and eventual revenue ramp-up, the company could run out of cash.

– Management Turnover & Governance: The sudden change in financial leadership is another concern. Nanox’s long-time CFO, Ran Daniel, will step down effective July 31, 2026 (after five years with the company) (www.globenewswire.com). A new CFO from outside (Guy Nathanzon, from Valens Semiconductor) has been appointed to take over (intellectia.ai). While succession planning is a normal course of business, a CFO transition during such a critical period raises questions. Investors often view CFO departures as potential red flags, wondering if there were any disagreements over financial strategy or if it signals distress (Nanox stated the departure was not due to any disagreement) (www.tipranks.com). Moreover, the CEO role has also seen changes in recent years (Nanox’s founder Ran Poliakine ceded CEO duties to Erez Meltzer, who leads the company now). Effective execution will depend on how well the new management team steers the company. Any further turnover or lack of experienced oversight could hinder Nanox’s ability to navigate its challenges. Corporate governance risk is also something to monitor given the company’s headquarters in Israel and global operations – alignment of management’s actions with shareholder interests will be under the microscope, especially in light of the legal investigations.

In summary, Nanox is a high-risk, high-reward story. The red flags – from unproven tech and recurring losses to legal probes and dilution – suggest a very precarious situation. Prospective investors should be prepared for volatility and the possibility that the company’s ambitious vision may not come to fruition.

Open Questions & Outlook

Looking ahead, several open questions remain about NNOX’s future trajectory, which investors and analysts will be watching closely:

– Can Nanox Hit Its 2026 Growth Targets? – The company reiterated a full-year 2026 revenue outlook of $35 million (nearly triple the 2025 actual revenue of $13M) (intellectia.ai). Achieving this would require a dramatic increase in system deployments and service usage in the coming quarters. Is this target realistic? It implies that dozens of Nanox.ARC units would need to be installed and generating revenue (either via sales or per-scan service fees) in 2026. Meeting the forecast will depend on successful production, delivery, and onboarding of new customers, as well as any regulatory clearances needed for broader use. Failure to deliver on this guidance could further erode credibility, while meeting it might restore some market confidence.

– How Will the Korean Chip Facility Impairment Impact Operations? – Nanox took a $17.5M impairment charge related to restructuring its Korean chip manufacturing facility (www.globenewswire.com). This write-down raises questions about the status of Nanox’s proprietary X-ray source production. Was this facility shut down or repurposed due to technical issues or cost concerns? If the in-house chip manufacturing effort stumbled, can Nanox secure a reliable supply of its nano-cathode X-ray chips elsewhere (e.g., through outsourcing or a technology partner)? The company’s ability to produce its core hardware components at scale is critical to its success. Clarity on the new manufacturing strategy – and whether additional investments or delays will result – is an important open question. Investors will want to know if this impairment was a one-time setback or a sign of deeper production challenges.

– Will Regulatory Approvals Expand in Time? – Nanox’s roadmap depends on regulatory clearance to broaden the usage of its imaging system. In August 2024, the company submitted a new 510(k) application to the U.S. FDA to expand Nanox.ARC’s indications to general use (e.g. chest imaging and beyond) (investors.nanox.vision). The outcome and timing of this submission remain uncertain. Will the FDA grant wider clearance for the multi-source Nanox.ARC, and if so, when? Conversely, any significant FDA request for more data or a delay could slow the rollout. Beyond the U.S., Nanox will also need approvals in other large markets. How efficiently can the company navigate these regulatory processes in parallel? This open question ties directly to market adoption – broader clearance could open larger portions of the imaging market to Nanox, whereas limited indications might confine it to niche uses initially.

– What Will the Kirby McInerney Investigation Uncover? – The ongoing shareholder rights investigation by Kirby McInerney LLP is another uncertainty (www.globenewswire.com). As of late April 2026, no lawsuit had been filed yet (www.globenewswire.com). The investigation is probing whether Nano-X or its executives engaged in any securities fraud or unlawful business practices, particularly around the disclosure of the Q4 results and CFO transition. Open questions include: Will this investigation find evidence of wrongdoing (e.g., that Nanox misled investors about its financial health or plans), potentially leading to a new lawsuit or regulatory action? Or will it conclude without further incident? The outcome could influence shareholder sentiment and legal liabilities. Investors should watch for any official findings or class-action filings in the coming months.

– How Will New Management Steer the Company? – With a new CFO joining in mid-2026 and the company’s operational phase ramping up, how will the leadership transition play out? Guy Nathanzon (incoming CFO) comes from a semiconductor background; will his expertise help improve operational efficiency and investor communication? Moreover, can CEO Erez Meltzer and the team execute a turnaround – cutting unnecessary costs, focusing the strategy, and possibly bringing in strategic partners? The strategic direction (for example, whether Nanox continues to go it alone or seeks alliances with established imaging companies or healthcare providers) is an open question. Any shifts in strategy or leadership approach will be important to monitor.

Overall, Nano-X Imaging’s story is approaching a critical juncture. The next 12-18 months will likely determine whether Nanox can transition from a promising concept to a commercially viable enterprise. Investors will be looking for concrete evidence of traction – such as an increasing installed base of Nanox.ARC systems, growing scan volumes, partnership announcements, or positive clinical feedback – to justify the company’s existence and valuation. In parallel, shoring up the balance sheet is essential: a capital raise (possibly from that $100M shelf) or other financing deal could occur soon. The balance between dilution and survival will be a key theme for existing shareholders.

In conclusion, NNOX remains a high-risk investment. The concept of democratizing imaging is compelling, but execution has proven challenging and filled with setbacks. With legal eyes watching and cash running low, Nanox is under pressure to deliver results in 2026. Whether it can do so – and thus silence its skeptics – is the million-dollar question. Investors and analysts should keep a close watch on the company’s quarterly updates and any developments from the ongoing investigation. For now, caution is warranted, and those who have suffered losses in NNOX may indeed want to stay informed about their legal rights (as Kirby McInerney’s alert suggests). (www.globenewswire.com) (www.globenewswire.com) The coming quarters will reveal if Nanox’s revolutionary vision will finally start converting into reality, or if further disappointments lie ahead.

Sources: The information in this report is based on Nano-X Imaging’s SEC filings, official press releases, and credible financial news. Key sources include the company’s 20-F annual report (www.sec.gov) (www.sec.gov) (www.sec.gov), investor presentations and earnings updates (investors.nanox.vision) (intellectia.ai), as well as independent analyses and news coverage from GlobeNewswire, Business Wire, Seeking Alpha, and others (www.globenewswire.com) (www.businesswire.com) (www.fool.com). All data and citations are provided inline for verification. Investors are encouraged to review these filings and releases for a fuller understanding of NNOX’s disclosures and risk factors.

For informational purposes only; not investment advice.